Published in Br J Pharmacol on October 29, 2007
The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol (2013) 5.57
Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev (2011) 2.22
Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation. Blood (2012) 1.64
Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood-brain barrier leakage and inflammation. J Cereb Blood Flow Metab (2010) 1.28
Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol (2011) 1.21
Physiology of endothelin and the kidney. Compr Physiol (2011) 1.08
The cardiovascular physiology and pharmacology of endothelin-1. Adv Pharmacol (2010) 1.01
Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol (2011) 1.01
The role of the paracrine/autocrine mediator endothelin-1 in regulation of cardiac contractility and growth. Br J Pharmacol (2013) 1.00
Vascular effects of phytoestrogens and alternative menopausal hormone therapy in cardiovascular disease. Mini Rev Med Chem (2012) 0.99
Endothelium-derived endothelin-1. Pflugers Arch (2009) 0.97
Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur Heart J (2011) 0.95
Cardiorenal syndrome: new developments in the understanding and pharmacologic management. Clin J Am Soc Nephrol (2013) 0.91
Immature endothelial cells initiate endothelin-mediated constriction of newborn arteries. J Physiol (2016) 0.89
Endothelin-1, aging and hypertension. Curr Opin Cardiol (2008) 0.88
Working under pressure: coronary arteries and the endothelin system. Am J Physiol Regul Integr Comp Physiol (2010) 0.88
Endothelins and their receptors in cancer: identification of therapeutic targets. Pharmacol Res (2011) 0.85
Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12. Br J Pharmacol (2014) 0.85
Molecular pathogenesis of myocardial remodeling and new potential therapeutic targets in chronic heart failure. Ital J Pediatr (2012) 0.85
Cardioprotective signaling by endothelin. Trends Cardiovasc Med (2008) 0.84
News from Tartary: an ethnopharmacological approach to drug and therapeutic discovery. Br J Clin Pharmacol (2016) 0.84
Key advances in antihypertensive treatment. Nat Rev Cardiol (2012) 0.84
Endothelin and hepatic wound healing. Pharmacol Res (2011) 0.84
O-GlcNAcylation: a novel pathway contributing to the effects of endothelin in the vasculature. Am J Physiol Regul Integr Comp Physiol (2010) 0.84
Vascular endothelium derived endothelin-1 is required for normal heart function after chronic pressure overload in mice. PLoS One (2014) 0.83
Stimuli of sensory-motor nerves terminate arterial contractile effects of endothelin-1 by CGRP and dissociation of ET-1/ET(A)-receptor complexes. PLoS One (2010) 0.82
G-protein βγ subunits in vasorelaxing and anti-endothelinergic effects of calcitonin gene-related peptide. Br J Pharmacol (2012) 0.81
UK-414,495, a selective inhibitor of neutral endopeptidase, potentiates pelvic nerve-stimulated increases in female genital blood flow in the anaesthetized rabbit. Br J Pharmacol (2010) 0.80
Dissecting the complex physiology of endothelin: new lessons from genetic models. Hypertension (2010) 0.80
Recent insights in the paracrine modulation of cardiomyocyte contractility by cardiac endothelial cells. Biomed Res Int (2014) 0.79
Discovery of inhibitors of insulin-regulated aminopeptidase as cognitive enhancers. Int J Hypertens (2012) 0.78
Endothelin-1 and endothelin-2 initiate and maintain contractile responses by different mechanisms in rat mesenteric and cerebral arteries. Br J Pharmacol (2013) 0.78
New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon? Curr Hypertens Rep (2015) 0.78
EndothelinA-endothelinB receptor cross-talk in rat basilar artery in situ. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.78
Right heart failure: toward a common language. Pulm Circ (2013) 0.78
Macitentan for the treatment of pulmonary arterial hypertension. Vasc Health Risk Manag (2014) 0.77
Agonist-dependent modulation of arterial endothelinA receptor function. Br J Pharmacol (2012) 0.77
Pulmonary artery smooth muscle cell endothelin-1 expression modulates the pulmonary vascular response to chronic hypoxia. Am J Physiol Lung Cell Mol Physiol (2014) 0.76
Association of endothelin-1 expression and cartilaginous endplate degeneration in humans. PLoS One (2013) 0.76
Pharmacological management of cardiorenal syndromes. Int J Nephrol (2011) 0.76
Selective endothelin A receptor antagonism with sitaxentan reduces neointimal lesion size in a mouse model of intraluminal injury. Br J Pharmacol (2015) 0.75
Effect of small hairpin RNA targeting endothelin-converting enzyme-1 in monocrotaline-induced pulmonary hypertensive rats. J Korean Med Sci (2012) 0.75
Re-sensitization of neuropeptide receptors: should we stop the recycling? Br J Pharmacol (2009) 0.75
Smooth Muscle Endothelin B Receptors Regulate Blood Pressure but Not Vascular Function or Neointimal Remodeling. Hypertension (2016) 0.75
Endothelin-1 shifts the mediator of bradykinin-induced relaxation from NO to H2 O2 in resistance arteries from patients with cardiovascular disease. Br J Pharmacol (2016) 0.75
Selective endothelin-1 receptor type A inhibition in subjects undergoing cardiac surgery with preexisting left ventricular dysfunction: Influence on early postoperative hemodynamics. J Thorac Cardiovasc Surg (2010) 0.75
Adaptations of the endothelin system after exercise training in a porcine model of ischemic heart disease. Microcirculation (2015) 0.75
Endothelin-1 promotes hypertrophic remodelling of cardiac myocytes by activating sustained signalling and transcription downstream of endothelin type A receptors. Cell Signal (2017) 0.75
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 40.02
A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 27.60
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med (1996) 12.77
Bosentan therapy for pulmonary arterial hypertension. N Engl J Med (2002) 11.18
The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A (1989) 7.41
Cloning and expression of a cDNA encoding an endothelin receptor. Nature (1991) 7.26
Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature (1991) 7.11
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 6.88
Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med (1978) 5.04
Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature (1994) 5.00
Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet (1994) 4.90
Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev (1994) 4.19
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum (2004) 3.46
The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med (1998) 2.90
Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med (1991) 2.88
Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest (2004) 2.66
Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med (2003) 2.64
Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A (1994) 2.43
Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol (2006) 2.19
Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther (1994) 2.14
Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain. Science (1988) 2.11
The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther (2001) 2.10
Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol (1985) 1.97
Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest (2002) 1.94
Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol (2005) 1.82
Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun (1989) 1.79
Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans? Trends Pharmacol Sci (1994) 1.79
Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res (1999) 1.78
Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem (1995) 1.73
Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation (2004) 1.65
Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest (2000) 1.65
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol (2003) 1.62
Endothelins in the normal and diseased kidney. Am J Kidney Dis (1997) 1.58
Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol (2003) 1.56
Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res (1993) 1.56
Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet (1995) 1.51
Cloning and functional expression of human cDNA for the ETB endothelin receptor. Biochem Biophys Res Commun (1991) 1.49
Discrepant distribution of big endothelin (ET)-1 and ET receptors in the pulmonary artery. Eur Respir J (2001) 1.48
Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation (1996) 1.47
The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol (2006) 1.42
Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther (1996) 1.38
Historical review: Endothelin. Trends Pharmacol Sci (2004) 1.38
International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev (2002) 1.37
Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest (2000) 1.36
Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J Biol Chem (1993) 1.35
Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension (1999) 1.34
Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol Med (Maywood) (2006) 1.31
Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol (2002) 1.28
Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation (2004) 1.27
Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J Biol Chem (2004) 1.26
Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt. Hypertension (2006) 1.26
Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther (1996) 1.24
Endothelin receptor antagonists. Pharmacol Ther (2005) 1.24
Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension (1995) 1.22
Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension (1999) 1.21
Sustained coronary vasoconstriction provoked by a peptidergic substance released from endothelial cells in culture. J Pharmacol Exp Ther (1986) 1.17
Molecular characterization of human and bovine endothelin converting enzyme (ECE-1). FEBS Lett (1994) 1.16
In vitro biological profile of a highly potent novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor. J Cardiovasc Pharmacol (1992) 1.15
Organ distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expression. J Clin Invest (1992) 1.15
Endothelin-1 mRNA is widely expressed in porcine and human tissues. J Clin Invest (1990) 1.13
Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther (1999) 1.13
The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther (1996) 1.12
A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter molecular cloning and characterization. Eur J Biochem (1999) 1.12
Role of neutral endopeptidase in the metabolism of endothelin. Hypertension (1992) 1.10
Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther (2002) 1.05
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity. J Med Chem (1999) 1.04
Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. Biochem Biophys Res Commun (1990) 1.04
Activation of endothelin ETA receptors masks the constrictor role of endothelin ETB receptors in rat isolated small mesenteric arteries. Br J Pharmacol (1997) 1.03
Endothelin-converting enzymes. FASEB J (1992) 1.03
Raynaud's phenomenon. Joint Bone Spine (2006) 1.02
Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells. Mol Pharmacol (1993) 1.00
Novel activity of endothelin-converting enzyme: hydrolysis of bradykinin. Biochem J (1997) 1.00
The fate of radioiodinated endothelin-1 and endothelin-3 in the rat. J Cardiovasc Pharmacol (1989) 1.00
Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists. J Med Chem (1996) 1.00
Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation (1998) 0.99
Endothelin receptor B is required for the expansion of melanocyte precursors and malignant melanoma. Int J Dev Biol (2005) 0.99
Clinical trials of endothelin antagonists in heart failure: a question of dose? Exp Biol Med (Maywood) (2006) 0.99
Secretory pathways in endothelin synthesis. Br J Pharmacol (1999) 0.98
Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology (Oxford) (2003) 0.97
Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats. Am J Physiol Lung Cell Mol Physiol (2002) 0.97
Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther (1997) 0.97
Synergistic inhibition by BQ-123 and BQ-788 of endothelin-1-induced contractions of the rabbit pulmonary artery. Br J Pharmacol (1994) 0.96
Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin converting enzyme. Jpn J Pharmacol (2000) 0.96
Cardio-circulatory effects of beta-adrenergic blockade in organic heart disease. Comparison between propranolol and CIBA 39,089-Ba. Br Heart J (1968) 0.96
WS75624 A and B, new endothelin converting enzyme inhibitors isolated from Saccharothrix sp. No. 75624. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. J Antibiot (Tokyo) (1995) 0.96
Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ET B receptors in vivo. Br J Pharmacol (2005) 0.96
Characterization of contractile endothelin and angiotensin receptors in human resistance arteries: evidence for two endothelin and one angiotensin receptor. Biochem Biophys Res Commun (1994) 0.96
Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. J Pharmacol Exp Ther (2000) 0.95
Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem (1997) 0.95
In vitro and in vivo studies with a series of hexapeptide endothelin antagonists. J Cardiovasc Pharmacol (1993) 0.94
Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest (2005) 0.94
Role of mast cell chymase in the extracellular processing of big-endothelin-1 to endothelin-1 in the perfused rat lung. Biochem Pharmacol (1992) 0.94
The crystal structure of human endothelin. Nat Struct Biol (1994) 0.94
Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure. Lancet (1998) 0.93
Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation (2001) 0.92
B-90063, a novel endothelin converting enzyme inhibitor isolated from a new marine bacterium, Blastobacter sp. SANK 71894. J Antibiot (Tokyo) (1998) 0.91
RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol (2003) 0.91
Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens (1998) 4.94
Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet (1994) 4.90
Differential dynamics of alpha 5 integrin, paxillin, and alpha-actinin during formation and disassembly of adhesions in migrating cells. J Cell Biol (2001) 3.99
The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol (2000) 3.43
Core content of a course in clinical pharmacology. Br J Clin Pharmacol (1997) 2.99
Factors related to first dose hypotensive effect of captopril: prediction and treatment. Br Med J (Clin Res Ed) (1983) 2.90
Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens (1993) 2.59
Ultrasonic hydrophone based on short in-fiber bragg gratings. Appl Opt (1998) 2.35
Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol (1999) 2.35
The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci (Lond) (1993) 2.18
Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br J Clin Pharmacol (2001) 1.97
Screening for human immunodeficiency virus: a survey of British clinical pharmacology units. Br J Clin Pharmacol (1993) 1.85
Increased augmentation index and systolic stress in type 1 diabetes mellitus. QJM (2000) 1.84
Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation (1999) 1.79
Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol (2001) 1.77
Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol (1989) 1.68
Uric acid reduces exercise-induced oxidative stress in healthy adults. Clin Sci (Lond) (2003) 1.66
Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest (1997) 1.65
Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation (1998) 1.61
L-NMMA increases blood pressure in man. Lancet (1993) 1.60
Contribution of parental blood pressures to association between low birth weight and adult high blood pressure: cross sectional study. BMJ (1998) 1.60
Developing a core curriculum in clinical pharmacology and therapeutics: a Delphi study. Br J Clin Pharmacol (1997) 1.58
Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci (2001) 1.52
Microvascular correlates of blood pressure, plasma glucose, and insulin resistance in health. Cardiovasc Res (2002) 1.51
Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens (1998) 1.48
Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation (1996) 1.47
32-km distributed temperature sensor based on Brillouin loss in an optical fiber. Opt Lett (1993) 1.46
Aortic pulse-wave velocity. Lancet (1999) 1.45
Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man. Cardiovasc Res (2000) 1.43
Transversal and longitudinal images from the retina of the living eye using low coherence reflectometry. J Biomed Opt (1998) 1.36
Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology (2006) 1.34
Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation (2001) 1.32
Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol (1989) 1.32
Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation (1995) 1.31
Blood glucose monitors: a laboratory and patient assessment. Br Med J (1980) 1.30
Comparison of forearm vasodilatation to substance P and acetylcholine: contribution of nitric oxide. Clin Sci (Lond) (1997) 1.27
Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart (2005) 1.26
Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med (2002) 1.24
Direct measurement of intracellular pH changes in Xenopus eggs at fertilization and cleavage. J Cell Biol (1981) 1.23
Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension (1999) 1.21
Pulse wave analysis and arterial stiffness. J Cardiovasc Pharmacol (1998) 1.21
Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab (1995) 1.19
Measurement of plasma angiotensin II. Clin Sci (Lond) (1985) 1.19
31P NMR reveals increased intracellular pH after fertilization in Xenopus eggs. Proc Natl Acad Sci U S A (1981) 1.18
An electrical block is required to prevent polyspermy in eggs fertilized by natural mating of Xenopus laevis. Dev Biol (1982) 1.18
Simultaneous en-face imaging of two layers in the human retina by low-coherence reflectometry. Opt Lett (1997) 1.17
Pulse transit time measured from the ECG: an unreliable marker of beat-to-beat blood pressure. J Appl Physiol (1985) (2005) 1.16
Peripheral endothelial dysfunction in normal pressure glaucoma. Invest Ophthalmol Vis Sci (1999) 1.16
Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. Biochem Biophys Res Commun (2000) 1.16
Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology (2000) 1.14
The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther (1996) 1.12
Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation (1998) 1.11
Classification of alpha 2-macroglobulin-cytokine interactions based on affinity of noncovalent association in solution under apparent equilibrium conditions. J Biol Chem (1994) 1.11
Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation (1996) 1.11
Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol (2001) 1.08
Scottish Medicines Consortium: an overview of rapid new drug assessment in Scotland. Scott Med J (2007) 1.08
Cortisol inhibits cholinergic vasodilation in the human forearm. Am J Hypertens (2000) 1.07
Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man. J Physiol (2001) 1.05
Peripheral vascular tone in patients with cirrhosis: role of the renin-angiotensin and sympathetic nervous systems. Cardiovasc Res (1998) 1.04
Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide. Gut (2003) 1.04
Effects of estrogen replacement on infarct size, cardiac remodeling, and the endothelin system after myocardial infarction in ovariectomized rats. Circulation (2000) 1.03
Activation of endothelin ETA receptors masks the constrictor role of endothelin ETB receptors in rat isolated small mesenteric arteries. Br J Pharmacol (1997) 1.03
Fertilization potential and electrical properties of the Xenopus laevis egg. Dev Biol (1985) 1.02
Studies with iontophoretic administration of drugs to human dermal vessels in vivo: cholinergic vasodilatation is mediated by dilator prostanoids rather than nitric oxide. Br J Clin Pharmacol (1998) 1.02
Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. Hepatology (2001) 1.01
Hyperuricaemia does not impair cardiovascular function in healthy adults. Heart (2004) 1.01
Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. Br J Clin Pharmacol (1997) 1.01
An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost (1997) 1.00
Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial. QJM (2009) 1.00
Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation (1998) 0.99
Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension (1998) 0.99
Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation (1991) 0.99
Coherence imaging by use of a Newton rings sampling function. Opt Lett (1996) 0.98
Forearm vasoconstriction to endothelin-1 is mediated by ETA and ETB receptors in vivo in humans. J Cardiovasc Pharmacol (1995) 0.98
S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. Br J Pharmacol (2000) 0.97
Relationship between plasma sialic acid concentration and microvascular and macrovascular complications in type 1 diabetes: the EURODIAB Complications Study. Diabetes Care (2001) 0.96
Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia (2007) 0.96
Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation (1996) 0.95
Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation (2001) 0.95
Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. Heart (1996) 0.94
Ultrasound findings in renal parenchymal disease: comparison with histological appearances. Clin Radiol (1994) 0.94
The Trevor Howell Lecture. Age, arterial stiffness and the endothelium. Age Ageing (1997) 0.93
Alpha 2-macroglobulin and the alpha 2-macroglobulin receptor/LRP. A growth regulatory axis. Ann N Y Acad Sci (1994) 0.93
Enalapril in hypertension with renal artery stenosis: long-term follow-up and effects on renal function. J Hypertens Suppl (1984) 0.93
Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int (1998) 0.93
Similarity between the suprasystolic wideband external pulse wave and the first derivative of the intra-arterial pulse wave. Br J Anaesth (2007) 0.92
Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography. Heart (2000) 0.92
Uric acid as a risk factor for cardiovascular disease. QJM (2000) 0.90
Prolonged effect of a novel S-nitrosated glyco-amino acid in endothelium-denuded rat femoral arteries: potential as a slow release nitric oxide donor drug. Br J Pharmacol (1997) 0.90
Vascular cell responsiveness to Toll-like receptor ligands in carotid atheroma. Eur J Clin Invest (2008) 0.90
Seasonal variation in glucocorticoid activity in healthy men. J Clin Endocrinol Metab (1997) 0.90
Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery. Heart (1999) 0.90
Interleukin-4 and IL-10 bind covalently to activated human alpha2-macroglobulin by a mechanism that requires Cys949. J Interferon Cytokine Res (2000) 0.90
Local L-NG-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm. Br J Clin Pharmacol (1994) 0.89
N-Substituted analogues of S-nitroso-N-acetyl-D,L-penicillamine: chemical stability and prolonged nitric oxide mediated vasodilatation in isolated rat femoral arteries. Br J Pharmacol (1999) 0.89
Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. J Am Coll Cardiol (2001) 0.89
Relation between ionic coupling and morphology of established cells in culture. Exp Cell Res (1973) 0.89